MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy

Prostate specific antigen (PSA) remains the most used test to assess the response after therapies including the radiation therapy (RT). Apparent diffusion coefficient (ADC) derived from the conventional diffusionweighted imaging (DWI), as a part of noncontrast or biparametric MRI (bpMRI) (T2-weighte...

Full description

Saved in:
Bibliographic Details
Published in:Urology research and practice 2021-11, Vol.47 (6), p.448
Main Authors: Scialpi, Michele, Martorana, Eugenio, Scialpi, Pietro, Alfredo D’Andrea, Mancioli, Francesco Maria, Mignogna, Marcello, Aldo Di Blasi, Trippa, Fabio
Format: Article
Language:English
Subjects:
Antigens
Biomarkers
Cancer therapies
Conflicts of interest
Hospitals
Localization
Magnetic resonance imaging
Prostate cancer
Radiation therapy
Urology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate specific antigen (PSA) remains the most used test to assess the response after therapies including the radiation therapy (RT). Apparent diffusion coefficient (ADC) derived from the conventional diffusionweighted imaging (DWI), as a part of noncontrast or biparametric MRI (bpMRI) (T2-weighted and DWI), offers diagnostic accuracy and cancer detection rate equivalent to that of multiparametric MRI. Cellular changes induced by RT can be quali-qualitatively demonstrated as early as 3months after RT as an increase in the signal intensity of the tumor on the ADC map. ADC, in association with PSA, represents a potential biomarker imaging for evaluating treatment efficacy in PCa both during and shortly after RT.
ISSN:2980-1478
DOI:10.5152/tud.2021.21274